In 2020, the results of a randomised phase 3 trial ("ProPSMA study") was published comparing Gallium-68 PSMA PET/CT to standard imaging (CT and bone scan). This 300 patient study conducted at 10 study sites demonstrated superior accuracy of PSMA PET/CT (92% vs 65%), higher significant change in management (28% vs 15%), less equivocal/uncertain imaging findings (7% vs 23%) and lower radiation exposure (10 mSv vs 19 mSv). The study concludes that PSMA PET/CT is a suitable replacement for conventional imaging, providing superior accuracy, to the combined findings of CT and bone scanning. This new technology was approved by the FDA on Dec 1, 2020. A dual-modality small molecule that is positron-emitting (18F) and fluorescent targets PSMA and was tested in humans. The molecule found the location of primary and metastatic prostate cancer by PET, fluorescence-guided removal of cancer, and detects single cancer cells in tissue margins.